Avin Aggarwal1, Helen S Te2, Elizabeth C Verna3, Archita P Desai4. 1. Gastroenterology and Hepatology, Comprehensive Digestive Institute of Nevada, Las Vegas, NV. 2. Center for Liver Diseases, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medicine, Chicago, IL. 3. Center for Liver Disease and Transplantation, Columbia University, New York, NY. 4. Department of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN.
Abstract
Recurrence of hepatocellular carcinoma (HCC) is an important predictor of survival after liver transplantation (LT). Recent studies show that early diagnosis, aggressive treatment, and surveillance may improve outcomes after HCC recurrence. We sought to determine the current practices and policies regarding surveillance for HCC recurrence after LT. METHODS: We conducted a web-based national survey of adult liver transplant centers in the United States to capture center-specific details of HCC surveillance post-LT. Responses were analyzed to generate numerical and graphical summaries. RESULTS: Of 101 eligible adult liver transplant centers, 48 (48%) centers across the United States responded to the survey. Among the participating centers, 79% stratified transplant recipients for HCC recurrence risk, while 19% did not have any risk stratification protocol. Explant microvascular invasion (mVI) was the most common factor used in risk stratification. Use of pretransplant serum biomarkers such as alpha-fetoprotein (AFP) was variable, with only 48% of the participating centers reporting specific "cutoff" values. While a majority of centers (88%) reported having a routine imaging protocol for HCC recurrence surveillance, there was considerable heterogeneity in terms of frequency and duration of such surveillance. Of the centers that did risk stratify patients to identify those at higher risk of HCC recurrence, about 50% did not change their surveillance protocol. CONCLUSIONS: Our study affirms significant variability in center practices, and our results reflect the need for high-quality studies to guide risk stratification and surveillance for HCC recurrence.
Recurrence of hepatocellular carcinoma (HCC) is an important predictor of survival after liver transplantation (LT). Recent studies show that early diagnosis, aggressive treatment, and surveillance may improve outcomes after HCC recurrence. We sought to determine the current practices and policies regarding surveillance for HCC recurrence after LT. METHODS: We conducted a web-based national survey of adult liver transplant centers in the United States to capture center-specific details of HCC surveillance post-LT. Responses were analyzed to generate numerical and graphical summaries. RESULTS: Of 101 eligible adult liver transplant centers, 48 (48%) centers across the United States responded to the survey. Among the participating centers, 79% stratified transplant recipients for HCC recurrence risk, while 19% did not have any risk stratification protocol. Explant microvascular invasion (mVI) was the most common factor used in risk stratification. Use of pretransplant serum biomarkers such as alpha-fetoprotein (AFP) was variable, with only 48% of the participating centers reporting specific "cutoff" values. While a majority of centers (88%) reported having a routine imaging protocol for HCC recurrence surveillance, there was considerable heterogeneity in terms of frequency and duration of such surveillance. Of the centers that did risk stratify patients to identify those at higher risk of HCC recurrence, about 50% did not change their surveillance protocol. CONCLUSIONS: Our study affirms significant variability in center practices, and our results reflect the need for high-quality studies to guide risk stratification and surveillance for HCC recurrence.
Authors: Roongruedee Chaiteerakij; Xiaodan Zhang; Benyam D Addissie; Essa A Mohamed; William S Harmsen; Paul J Theobald; Brian E Peters; Joseph G Balsanek; Melissa M Ward; Nasra H Giama; Catherine D Moser; Abdul M Oseini; Naoki Umeda; Sudhakar Venkatesh; Denise M Harnois; Michael R Charlton; Hiroyuki Yamada; Shinji Satomura; Alicia Algeciras-Schimnich; Melissa R Snyder; Terry M Therneau; Lewis R Roberts Journal: Liver Transpl Date: 2015-05 Impact factor: 5.799
Authors: Ju Dong Yang; Joseph J Larson; Kymberly D Watt; Alina M Allen; Russell H Wiesner; Gregory J Gores; Lewis R Roberts; Julie A Heimbach; Michael D Leise Journal: Clin Gastroenterol Hepatol Date: 2016-12-21 Impact factor: 11.382
Authors: G Sapisochin; N Goldaracena; S Astete; J M Laurence; D Davidson; E Rafael; L Castells; C Sandroussi; I Bilbao; C Dopazo; D R Grant; J L Lázaro; M Caralt; A Ghanekar; I D McGilvray; L Lilly; M S Cattral; M Selzner; R Charco; P D Greig Journal: Ann Surg Oncol Date: 2014-12-04 Impact factor: 5.344
Authors: Quirino Lai; Alfonso W Avolio; Ivo Graziadei; Gerd Otto; Massimo Rossi; Giuseppe Tisone; Pierre Goffette; Wolfgang Vogel; Michael B Pitton; Jan Lerut Journal: Liver Transpl Date: 2013-10 Impact factor: 5.799
Authors: David D Lee; Gonzalo Sapisochin; Neil Mehta; Andre Gorgen; Kaitlyn R Musto; Hana Hajda; Francis Y Yao; David O Hodge; Rickey E Carter; Denise M Harnois Journal: Transplantation Date: 2020-10 Impact factor: 4.939
Authors: Elizabeth C Verna; Yuval A Patel; Avin Aggarwal; Archita P Desai; Catherine Frenette; Anjana A Pillai; Reena Salgia; Anil Seetharam; Pratima Sharma; Courtney Sherman; Georgios Tsoulfas; Francis Y Yao Journal: Am J Transplant Date: 2019-12-09 Impact factor: 8.086
Authors: Maria C van Hooff; Milan J Sonneveld; Jan N Ijzermans; Michail Doukas; Dave Sprengers; Herold J Metselaar; Caroline M den Hoed; Robert A de Man Journal: Cancers (Basel) Date: 2022-01-27 Impact factor: 6.639
Authors: Wojciech Andrzej Straś; Dariusz Wasiak; Beata Łągiewska; Olga Tronina; Marta Hreńczuk; Joanna Gotlib; Wojciech Lisik; Piotr Małkowski Journal: Ann Transplant Date: 2022-01-26 Impact factor: 1.530
Authors: Charlotte Costentin; Federico Piñero; Helena Degroote; Andrea Notarpaolo; Ilka F Boin; Karim Boudjema; Cinzia Baccaro; Luis G Podestá; Philippe Bachellier; Giuseppe Maria Ettorre; Jaime Poniachik; Fabrice Muscari; Fabrizio Dibenedetto; Sergio Hoyos Duque; Ephrem Salame; Umberto Cillo; Sebastian Marciano; Claire Vanlemmens; Stefano Fagiuoli; Patrizia Burra; Hans Van Vlierberghe; Daniel Cherqui; Quirino Lai; Marcelo Silva; Fernando Rubinstein; Christophe Duvoux Journal: JHEP Rep Date: 2022-02-02